{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:00:47Z","timestamp":1791903647140,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7666","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/nature23291","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T12:21:00Z","timestamp":1501590060000},"page":"234-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":529,"title":["Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS"],"prefix":"10.1038","volume":"548","author":[{"given":"Zhan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa S.","family":"Rodrik-Outmezguine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neilawattie M.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Drosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Hembrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Barbacid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"key":"BFnature23291_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","volume":"28","author":"Z Yao","year":"2015","unstructured":"Yao, Z. et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28, 370\u2013383 (2015)","journal-title":"Cancer Cell"},{"key":"BFnature23291_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855\u2013867 (2004)","journal-title":"Cell"},{"key":"BFnature23291_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/emboj.2010.7","volume":"29","author":"M Drosten","year":"2010","unstructured":"Drosten, M. et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29, 1091\u20131104 (2010)","journal-title":"EMBO J."},{"key":"BFnature23291_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209\u2013221 (2010)","journal-title":"Cell"},{"key":"BFnature23291_CR5","unstructured":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681\u20131696 (2015)"},{"key":"BFnature23291_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang, M. T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155\u2013163 (2016)","journal-title":"Nat. Biotechnol."},{"key":"BFnature23291_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/107327481402100307","volume":"21","author":"RD Hall","year":"2014","unstructured":"Hall, R. D. & Kudchadkar, R. R. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Contr. 21, 221\u2013230 (2014)","journal-title":"Cancer Contr."},{"key":"BFnature23291_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/s12885-015-1811-y","volume":"15","author":"G Zheng","year":"2015","unstructured":"Zheng, G. et al. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer 15, 779 (2015)","journal-title":"BMC Cancer"},{"key":"BFnature23291_CR9","doi-asserted-by":"publisher","unstructured":"Nieto, P. et al. A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature \n                    http:\/\/dx.doi.org\/10.1038\/nature23297\n                    \n                   (2017)","DOI":"10.1038\/nature23297"},{"key":"BFnature23291_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1158\/2159-8290.CD-15-0896","volume":"6","author":"SH Chen","year":"2016","unstructured":"Chen, S. H. et al. Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120. Cancer Discov. 6, 300\u2013315 (2016)","journal-title":"Cancer Discov."},{"key":"BFnature23291_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.molcel.2005.10.022","volume":"20","author":"MJ Garnett","year":"2005","unstructured":"Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963\u2013969 (2005)","journal-title":"Mol. Cell"},{"key":"BFnature23291_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427\u2013430 (2010)","journal-title":"Nature"},{"key":"BFnature23291_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","volume":"30","author":"Z Karoulia","year":"2016","unstructured":"Karoulia, Z. et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell 30, 485\u2013498 (2016)","journal-title":"Cancer Cell"},{"key":"BFnature23291_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387\u2013390 (2011)","journal-title":"Nature"},{"key":"BFnature23291_CR15","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1158\/0008-5472.CAN-10-0646","volume":"70","author":"H Yang","year":"2010","unstructured":"Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518\u20135527 (2010)","journal-title":"Cancer Res."},{"key":"BFnature23291_CR16","first-page":"251","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. JMD 17, 251\u2013264 (2015)","journal-title":"JMD"},{"key":"BFnature23291_CR17","first-page":"454","volume":"15","author":"T Hembrough","year":"2013","unstructured":"Hembrough, T. et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. JMD 15, 454\u2013465 (2013)","journal-title":"JMD"},{"key":"BFnature23291_CR18","doi-asserted-by":"publisher","first-page":"e100586","DOI":"10.1371\/journal.pone.0100586","volume":"9","author":"DV Catenacci","year":"2014","unstructured":"Catenacci, D. V. et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One 9, e100586 (2014)","journal-title":"PLoS One"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature23291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature23291","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nature23291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nature23291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:03:42Z","timestamp":1684418622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature23291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":18,"journal-issue":{"issue":"7666","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFnature23291"],"URL":"https:\/\/doi.org\/10.1038\/nature23291","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"5 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.R. is on the scientific advisory board of and receives research funding from Chugai, and is on the scientific advisory board of and owns stock in Beigene, Wellspring and Kura. N.R. is also on the scientific advisory board of Daiichi-Sankyo, Astra-Zeneca and Takeda, and is a consultant to Novartis. V.S.R.-O. is now an employee of Novartis Pharmaceutical Corporation as Precision Medicine Associate Director. F.C. is an employee at NantOmics, LLC. T.H. is the President of Proteomics at NantOmics and owns the stock.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}